Shanghai S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
25.3
CNY
+8.68%
+7.75%
+47.87%
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
August 17, 2020 at 03:40 am EDT
Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 1,174.552 million compared to CNY 1,168.694 million a year ago. Operating income was CNY 209.143 million compared to CNY 216.838 million a year ago. Net income was CNY 177.374 million compared to CNY 183.518 million a year ago. Basic earnings per share from continuing operations was CNY 0.312 compared to CNY 0.314 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 25
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 25
CI
Henan Lingrui Pharma Registers Chewable Asthma Drug in China
Apr. 19
MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-27
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-09
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-25
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-25
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-27
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-05
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-25
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-04-25
CI
Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 1, 2022 has expired with 19,086,325 shares, representing 3.39% for CNY 184.47 million.
22-01-30
CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.
22-01-03
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-27
CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.
21-10-07
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-30
CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.
21-07-02
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-27
CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.
21-04-01
CI
Henan Lingrui Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
21-02-01
CI
Henan Lingrui Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
21-01-31
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
20-10-27
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
20-08-17
CI
Henan Lingrui Pharmaceutical Co., Ltd. Announces Cash Dividend for 2019, Payable on June 19, 2020
20-06-11
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020
20-04-28
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
More about the company
1st Jan change
Capi.
+47.87% 1.97B +35.04% 5.92B -15.13% 4.51B -9.75% 3.15B +2.14% 3.1B -6.82% 2.42B -7.89% 1.68B +0.09% 1.65B -12.97% 1.53B +33.40% 1.38B
Alternative Medicine
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
HENAN LINGRUI PHARMACEUTICAL CO., LTD. 
